JPH0632630B2 - Method for producing protein antigen produced by pathogenic bacteria in livestock and poultry - Google Patents

Method for producing protein antigen produced by pathogenic bacteria in livestock and poultry

Info

Publication number
JPH0632630B2
JPH0632630B2 JP61021245A JP2124586A JPH0632630B2 JP H0632630 B2 JPH0632630 B2 JP H0632630B2 JP 61021245 A JP61021245 A JP 61021245A JP 2124586 A JP2124586 A JP 2124586A JP H0632630 B2 JPH0632630 B2 JP H0632630B2
Authority
JP
Japan
Prior art keywords
medium
semipermeable membrane
genus
antigen
protein
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
JP61021245A
Other languages
Japanese (ja)
Other versions
JPS62181797A (en
Inventor
輝武 矢挽
直 深見
厚 浜野
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
ZENKOKU NOGYO KYODOKUMIAI RENGOKAI
Original Assignee
ZENKOKU NOGYO KYODOKUMIAI RENGOKAI
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by ZENKOKU NOGYO KYODOKUMIAI RENGOKAI filed Critical ZENKOKU NOGYO KYODOKUMIAI RENGOKAI
Priority to JP61021245A priority Critical patent/JPH0632630B2/en
Publication of JPS62181797A publication Critical patent/JPS62181797A/en
Publication of JPH0632630B2 publication Critical patent/JPH0632630B2/en
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Description

【発明の詳細な説明】 (産業上の利用分野) 本発明は、感染症診断に用いられる家畜(禽)の病原性
細菌の産生する蛋白質抗原の製法に関する。
TECHNICAL FIELD The present invention relates to a method for producing a protein antigen produced by a pathogenic bacterium of livestock (poultry) used for infectious disease diagnosis.

(従来の技術) 最近の畜産業界の発展は目覚しく、特に生産性の向上を
目指し、多頭飼養による規模拡大には驚くべきものがあ
る。しかし、それにともなつて生産性の向上を阻害する
要因として慢性の疾病が畜産経営にとつて大きな脅威と
なつており、これの浄化が急務である。そのため、その
疾病(主に感染症)の診断が重要である。特に、その感
染症の診断を簡便で適確な診断法として、家畜(禽)の
病原性細菌の産生する蛋白質抗原を用いる診断法が好ま
しく採用されているが、この蛋白質抗原を大量に製造す
ることが要請されて居り、従来の製法として、液体培養
法を通じての下記の製法がある。即ち、先づ、液体培地
に病原性細菌を培養し、遠心分離あるいは過除菌によ
つて菌体と培地中に産生された蛋白質抗原を含む上清あ
るいは液とに分離し、その上清あるいは液を減圧濃
縮法ならびに限外過法(分画分子量の異なる幾つかの
限外過膜を用いる)を用いて、一定濃度に濃縮・精製
するか、また硫酸アンモニウム等の塩類を用い塩析によ
つて、その蛋白質抗原含有液を回収し使用する等の方法
がとられている。
(Prior Art) The recent development of the livestock industry has been remarkable, and especially for the purpose of improving productivity, the scale expansion by multi-breeding is surprising. However, along with this, chronic diseases pose a major threat to livestock management as a factor that impedes productivity improvement, and there is an urgent need to clean up these diseases. Therefore, diagnosis of the disease (mainly infectious disease) is important. In particular, a diagnostic method using a protein antigen produced by a pathogenic bacterium of domestic animals (poultry) is preferably adopted as a simple and accurate diagnostic method for the infectious disease, and a large amount of this protein antigen is produced. However, as a conventional manufacturing method, there is the following manufacturing method through a liquid culture method. That is, first, pathogenic bacteria are cultivated in a liquid medium, and separated by centrifugation or sterilization into bacterial cells and a supernatant or liquid containing the protein antigen produced in the medium, and the supernatant or The solution is concentrated and purified to a certain concentration using the vacuum concentration method and the ultrafiltration method (using several ultrafiltration membranes with different molecular weight cutoffs), or by salting out using salts such as ammonium sulfate. Then, methods such as collecting and using the protein antigen-containing liquid are taken.

又、別の製法として、次のようなものがある。即ち、液
体培地中に半透膜袋を懸垂し、その半透膜の袋中に菌液
(精製水、生理食塩液あるいは緩衝液に菌を懸濁)を入
れ、外液のある液体培地をマグネツト・スターラー等で
攪拌し乍ら培養し、培養後半透膜袋を取り出し、遠心分
離によつて菌体と菌液中に産生された蛋白質抗原を含む
上清とに分離し、その上清を半透膜チユーブに詰め、濃
縮剤で濃縮し、その抗原物質を回収する方法である。
Another method is as follows. That is, a semipermeable membrane bag is suspended in a liquid medium, and a bacterial solution (bacteria suspended in purified water, physiological saline, or a buffer solution) is placed in the semipermeable membrane bag, and a liquid medium containing an external liquid is added. After stirring and culturing with a magnetic stirrer, etc., the latter half of the culture permeable bag is taken out and separated by centrifugation into the bacterial cells and the supernatant containing the protein antigen produced in the bacterial solution, and the supernatant is separated. It is a method of collecting the antigenic substance by packing it in a semipermeable membrane tube and concentrating it with a concentrating agent.

(発明が解決しようとする問題点) 上記従来の製法には夫々次のような欠点がある。即ち、
上記の限外過を行う場合、培養細菌によつて産生され
たムコ多糖などの粘稠性物質あるいは培地中の獣・魚肉
エキス、ペプトン、あるいは獣畜などの血液や血清成分
などの種々の高分子量の成分によつて限外過がスムー
ズに進行しないため多くの時間を要し、またこの操作を
2回以上繰り返し行うことなどから、濃縮・精製工程が
煩雑でしかも,必要とする蛋白質抗原物質が限外過膜
に吸着されたりするので、その抗原物質の回収も悪い。
(Problems to be Solved by the Invention) The above conventional manufacturing methods have the following drawbacks. That is,
When performing the above-mentioned ultrafiltration, viscous substances such as mucopolysaccharides produced by cultured bacteria or animal / fish meat extract, peptone in the medium, or various high contents such as blood and serum components of animal / livestock etc. It takes a lot of time because the ultrafiltration does not proceed smoothly due to the molecular weight component, and since this operation is repeated twice or more, the concentration / purification process is complicated and the required protein antigen substance is required. Is also adsorbed on the ultrapermeate, so the recovery of the antigenic substance is also poor.

又、上記の遠心分離による上清あるいは過除菌による
液について、硫酸アンモニウム等の塩類を用いた塩析
法によつて蛋白質抗原を回収する場合は、大量の塩類を
少量ずつ加えるため長時間を要し、塩析後遠心分離を行
い、その沈渣を少量の精製水で溶解し、半透膜チユーブ
に詰め、その塩類を透析によつて除去しなければならな
い。それには大量の精製水、および生理食塩液、あるい
は緩衝液を用いる必要があり、その分離、精製、回収工
程が煩雑で時間も多く要し、しかも回収後の抗原物質の
蛋白変性による失活もみられる。
Further, when the protein antigen is recovered from the supernatant obtained by the above centrifugation or the liquid obtained by the eradication by a salting out method using salts such as ammonium sulfate, it takes a long time to add a large amount of salts little by little. After salting out, centrifugation must be carried out, the precipitate must be dissolved with a small amount of purified water, packed in a semipermeable membrane tube, and the salts must be removed by dialysis. For that purpose, it is necessary to use a large amount of purified water, physiological saline, or a buffer solution, and the separation, purification, and recovery steps are complicated and take a lot of time, and inactivation due to protein denaturation of the antigenic material after recovery is also observed. To be

又、上記の液体培地中に、半透膜袋を懸垂し、その半透
膜中に菌液を入れて培養する場合は、使用液体培地量あ
たりの蛋白質抗原物質の産生量が少なく、また、その回
収液には培地中に含まれる低分子量の色素等が混入し、
これら物質を除去するため、精製水、および生理食塩
液、あるいは緩衝液等で透析しても除去することが困難
で、精度の高い良質の抗原製品が得られない等の不都合
を伴なう。
Further, in the above liquid medium, a semipermeable membrane bag is suspended, and in the case of culturing by inserting a bacterial solution in the semipermeable membrane, the production amount of the protein antigenic substance per amount of the liquid medium used is small, and The recovered liquid is contaminated with low-molecular weight dyes contained in the medium,
Since these substances are removed, it is difficult to remove them even by dialysis with purified water, physiological saline solution, buffer solution or the like, which causes inconvenience that a highly accurate antigen product cannot be obtained.

(問題点を解決するための手段) 本発明は、かゝる上記従来法の欠点を除去し、従来法に
比し著しく簡単な製造工程で、短時間に、高収率で且つ
高品質に蛋白質抗原を製造し得るようにした家畜(禽)
の病原性細菌の産生する蛋白質抗原の製法を提供するも
ので、半固形培地上に該培地中の栄養成分は通過させる
が、蛋白質抗原を通過させない半透膜を付着し、その半
透膜上に家畜(禽)の病原性細菌の培養菌液を塗布し、
本培養を行い、蛋白質抗原を該半透膜上に産生させた
後、その半透膜をその産生した蛋白質抗原と共に半固形
培地から剥離し、次で該半透膜を洗浄し、得られた洗浄
液から該抗原を菌体と分離して回収することを特徴とす
る (実施例) 次に本発明の実施例を詳述する。
(Means for Solving Problems) The present invention eliminates the above-mentioned drawbacks of the conventional method, and achieves a high yield and high quality in a short time with a significantly simple manufacturing process as compared with the conventional method. Livestock (fowl) adapted to produce protein antigens
The method for producing a protein antigen produced by the pathogenic bacterium of claim 1, wherein a semipermeable membrane that allows nutrient components in the medium to pass but does not pass the protein antigen is attached to the semisolid medium, Apply the culture fluid of pathogenic bacteria of livestock (poultry) to
After the main culture was performed to produce the protein antigen on the semipermeable membrane, the semipermeable membrane was peeled from the semisolid medium together with the produced protein antigen, and then the semipermeable membrane was washed to obtain The present invention is characterized in that the antigen is separated from the microbial cells and collected from the washing solution (Example).

本発明によれば、半固形培地を使用する、その代表は、
一般に、寒天培地として知られているものである。病原
性細菌用の寒天培地は、ペプトン類、獣(魚)肉エキ
ス、酵母エキス、塩類、綿羊、馬、鶏、牛、豚、兎など
の血液、あるいは血清、ブトウ糖、デンプン等の糖類、
あるいはL−塩酸システイン、ヘミン等から適宜選択配
合し、これに1〜2%の割合の寒天を加え、加熱、溶解
し、主に高圧滅菌110℃〜121℃、10〜15分間)し、45〜
50℃に冷えてから滅菌ペトリ皿に15〜20ml注ぎ固めたも
のである。尚、血液又は血清を配合する場合は、これ以
外の成分組成のものを前記の高圧滅菌、冷却してから血
液又は血清を加えてよく攪拌、混合して寒天培地とす
る。次に、このように調製した所定組成の半固形培地上
に、半透膜を付着する。半透膜としては、家畜、家禽の
病原性細菌の産生する蛋白質抗原を通過させないものを
使用する。その蛋白質抗原の分子量は10,000〜200,00
0、更にサブユニツトとしてその多くの分子量は20,000
〜50,000であることから、分画分子量の範囲が3,500〜5
0,000のものを使用するのが一般的である。次に、その
半透膜上に、家畜(禽)の病原性細菌の培養菌液を塗布
する。その病原性細菌としては、たとえばアクチノマイ
セス(Actinomyces)属、ボルデテラ(Bordetella)
属、パスツレラ(Pasteurella)属、フソバクテリウム
(Fusobacterium)属、アクチノバチラス(Actinobacil
lus)属、ヘモフイルス(Haemophillus)属に属する細
菌が使用される。
According to the invention, a semi-solid medium is used, a representative of which is:
It is generally known as an agar medium. The agar medium for pathogenic bacteria includes peptones, beef (fish) meat extract, yeast extract, salts, blood such as cotton sheep, horses, chickens, cows, pigs and rabbits, or saccharides such as serum, butter sugar and starch,
Alternatively, L-cysteine hydrochloride, hemin, etc. are appropriately selected and blended, and 1 to 2% of agar is added thereto, and the mixture is heated and dissolved, and is autoclaved mainly at 110 ° C to 121 ° C for 10 to 15 minutes), 45 ~
It is cooled to 50 ° C and then poured into a sterile Petri dish in an amount of 15 to 20 ml to be solidified. When blood or serum is blended, the composition other than this is sterilized by high pressure and cooled, and then blood or serum is added and well stirred and mixed to obtain an agar medium. Next, a semipermeable membrane is attached on the semisolid medium having a predetermined composition thus prepared. As the semipermeable membrane, one that does not allow passage of protein antigens produced by pathogenic bacteria of livestock and poultry is used. The molecular weight of the protein antigen is 10,000-200,00
0, and most of them have a molecular weight of 20,000 as a subunit.
Since it is ~ 50,000, the range of molecular weight cutoff is 3,500 ~ 5
It is common to use the one of 0,000. Then, a culture solution of pathogenic bacteria of livestock (poultry) is applied onto the semipermeable membrane. Examples of the pathogenic bacterium include, for example, the genus Actinomyces, Bordetella.
Genus, Pasteurella genus, Fusobacterium genus, Actinobacillus
The bacterium belonging to the genus lus) and the genus Haemophillus is used.

かかる病原性細菌の具体例としては、たとえばストレプ
トコツカス・エクイシミレス(Streptococcus equisimi
lis)、ストレプトコツカス・ズイス(Streptococcus s
uis)、スタフィロコツカス・ハイカス(Staphylococcu
s hyicus subsp.hyicus)、スタフイロコツカス・アウ
レウス(Staphylococcus aureus)、アクチノマイセス
・ピオゲネス(Actinomyces pyogenes)、ボルデテラ・
ブロンヒセプテイカ(Bordetella bronchiseptica)、
ヘモフイルス・パラズイス(Haemophilus parasuis)、
アクチノパチラス・プロエロニユーモニア(Actinobaci
llus pleuropneumoniae)、パスツレラ・マルトシダ(P
asteurella multocida)、フソバクテリウム・ネクロフ
オラム(Fusobacterium necrophorum)等があり、それ
らの細菌が産生する蛋白質抗原ならびにその対象動物は
下記第1表に示される。
Specific examples of such pathogenic bacteria include, for example, Streptococcus equisimiles.
lis), Streptococcus s
uis), Staphylococcu
s hyicus subsp.hyicus), Staphylococcus aureus, Actinomyces pyogenes, Bordetella
Bordetella bronchiseptica,
Haemophilus parasuis,
Actinobaci
llus pleuropneumoniae), Pasteurella martosida (P
asteurella multocida), Fusobacterium necrophorum, etc., and protein antigens produced by these bacteria and their target animals are shown in Table 1 below.

即ち、予め滅菌処理した半固形培地面に貼つた特定の分
画分子量の半透膜上に、目的とする特定の蛋白質抗原を
産生する病原性細菌を予め培養した新鮮培養菌液の一定
量を置き、その菌液を均一に塗布する。これを、その菌
種に応じて、好気、嫌気、炭酸ガス置換などの所望の培
養条件下で、25〜40℃の培養温度で18時間〜14日培
養する(本培養)。この培養において、半固形培地に含
まれる蛋白質などの高分子物質が半透膜を通過して、移
植した該菌と接触することがない反面、培地中の塩類、
ビタミン、ペプチド、アミノ酸、およびその他の低分子
物質の栄養成分は半透膜を通過して該菌に供給され、そ
れらの栄養素によつて菌は発育する。該菌は発育にとも
ないその菌に応じた種類の蛋白質抗原物質を産生する。
しかしその産生された抗原物質は高分子のため半透膜を
通過して、培地中に拡散することはなく、半透膜上には
菌体と該菌が産生した蛋白質抗原物質および低分子量の
培地成分が残る。
That is, on a semipermeable membrane with a specific cut-off molecular weight pasted on the surface of a semi-solid medium that has been sterilized in advance, a certain amount of a fresh culture solution obtained by pre-culturing a pathogenic bacterium that produces a specific protein antigen of interest. Place and apply the bacterial solution evenly. This is cultivated for 18 hours to 14 days at a culturing temperature of 25 to 40 ° C. under the desired culturing conditions such as aerobic, anaerobic, and carbon dioxide substitution depending on the bacterial species (main culturing). In this culture, a polymeric substance such as a protein contained in the semi-solid medium passes through the semi-permeable membrane and does not come into contact with the transplanted bacterium, but salts in the medium,
The nutritional components of vitamins, peptides, amino acids, and other low molecular weight substances pass through the semipermeable membrane and are supplied to the bacterium, and the nutrients cause the bacterium to grow. As the bacterium grows, the bacterium produces a protein antigen substance of a type suitable for the bacterium.
However, since the produced antigenic substance passes through the semipermeable membrane because it is a polymer and does not diffuse into the medium, the bacterial cells and the protein antigenic substance produced by the bacterium and low molecular weight substances are not formed on the semipermeable membrane. Medium components remain.

尚、培地中の色素の多くは、蛋白質等の高分子物質と結
合しているため、半透膜を通過することがない。微量の
遊離色素も、寒天によつて固定せられるので半透膜を通
過して抗原物質側に混入することが防止される。
Many of the pigments in the medium do not pass through the semipermeable membrane because they are bound to high molecular substances such as proteins. Since a small amount of free dye is fixed by agar, it is prevented from passing through the semipermeable membrane and being mixed with the antigen substance side.

この本培養後、培地面の半透膜を剥ぎ取り、緩衝液でこ
れに付着している抗原物質等の残留物を洗い落とし、そ
の洗浄液について遠心分離を行うことで菌体と蛋白質抗
原物質を含む上清とに分離する。遠心分離は3,000〜15,
000rpmで、10〜60分間の範囲で操作すれば、菌体は
遠心管底に菌塊として残るので、上清液のみ回収する。
回収された上清液中には蛋白質抗原物質と低分子量の培
地成分および緩衝液の塩類等が含まれる。この上清液を
半透膜チユーブに詰め、市販の第1工業薬品(株)製A
Gガム、和光純薬(株)製ポリエチレングリコール#60
00などの濃縮剤で濃縮し、培地成分の低分子培地成分を
除去し、かくして、蛋白質抗原の濃度の高い溶液を得る
ことができる。
After this main culture, the semipermeable membrane on the medium surface is stripped off, the residue such as the antigenic substance adhering to it is washed off with a buffer solution, and the washing solution is centrifuged to contain the bacterial cells and protein antigenic substance. Separate into supernatant. Centrifugation is 3,000-15,
If the operation is performed at 000 rpm for 10 to 60 minutes, the bacterial cells will remain as a bacterial mass on the bottom of the centrifuge tube, so only the supernatant liquid is collected.
The recovered supernatant contains protein antigenic substances, low-molecular weight medium components, buffer salts, and the like. This supernatant liquid was packed in a semipermeable membrane tube, and commercially available from A Daiichi Kogyo Kagaku Co., Ltd.
G gum, polyethylene glycol # 60 manufactured by Wako Pure Chemical Industries, Ltd.
Concentration with a concentrating agent such as 00 removes the low molecular weight medium components of the medium components, and thus a solution with a high concentration of protein antigen can be obtained.

さらに、濃縮された蛋白質抗原溶液を半透膜チユーブに
入れたまゝ精製水で透析を繰り返すことによつて塩類な
どの低分子量を除去し、より純度の高い蛋白質抗原物質
を得ることもできる。回収された濃縮液即ち抗原は、ボ
ツクスタイトレーシヨンによつて活性単位を決定し、一
定の単位抗原になるように希釈液(緩衝液)を加え、蛋
白質抗原が変性、失活しない方法で凍結乾燥し、診断用
蛋白質抗原を得る。これで得られた本発明による診断用
抗原は、冷暗所などで長期間安定に保存することができ
る。
Further, the concentrated protein antigen solution may be put into a semipermeable membrane tube and repeatedly dialyzed with purified water to remove low molecular weights such as salts to obtain a protein antigen substance having higher purity. The recovered concentrated solution, that is, the antigen, is frozen by a method in which the activity unit is determined by the box titration method, and a diluent (buffer solution) is added so that a certain unit antigen is obtained, and the protein antigen is not denatured or inactivated. After drying, a diagnostic protein antigen is obtained. The diagnostic antigen of the present invention thus obtained can be stably stored for a long period of time in a cool and dark place.

尚、病原性細菌の菌株を分離し、純粋培養して本法の前
記本培養に用いる種菌又は元菌を作製する培養法は、従
来用いられる任意の培養法でよく、液体培養、半固形培
養などで、その培地組成は、前記の半固形培地のそれと
同じでよい。
Incidentally, the culture method of separating the pathogenic bacterium strain and producing the inoculum or original bacterium used in the main culture of the present method by pure culture may be any conventionally used culture method, such as liquid culture and semi-solid culture. Etc., the medium composition thereof may be the same as that of the semi-solid medium described above.

又、所定の病原性細菌の菌株は、動物用生物学的製剤協
会、農林水産省家畜衛生試験場などから容易に入手で
き、又各感染症に羅患している家畜から分離、固定した
ものを使用すればよい。
Strains of the specified pathogenic bacteria can be easily obtained from the Veterinary Biologics Association, the Ministry of Agriculture, Forestry and Fisheries, Animal Health Test Center, etc., and those isolated and fixed from livestock affected by each infectious disease should be used. You can use it.

次に更に本発明の具体的実施例につき説明する。Next, specific examples of the present invention will be described.

実施例 アクチノマイセス・ピオゲネス菌株(農林水産省家畜衛
生試験場から分与を受けたものを用いるか、あるいはア
クチノマイセス・ピオゲネス感染豚から本菌を分離し、
それからプロテアーゼ産生能の高い菌株を選択して使用
してもよい)を、半固形倍地である血液寒天培地に接種
し、嫌気条件下で、37℃、1〜2日培養し、寒天培地
上の集落を再度新しい血液寒天培地に移植し、37℃で
1〜2日間嫌気的に培養し、種菌を得る。ここまでは従
来法と同様である。
Example Actinomyces pyogenes strain (use one that has been distributed from the Ministry of Agriculture, Forestry and Fisheries Animal Health Laboratory, or isolate this bacterium from Actinomyces pyogenes infected pigs,
Then, a strain with high protease-producing ability may be selected and used) to inoculate a blood agar medium which is a semi-solid medium and cultured under anaerobic conditions at 37 ° C for 1 to 2 days. The resulting colonies are transplanted again to a fresh blood agar medium and anaerobically cultured at 37 ° C. for 1 to 2 days to obtain inoculum. Up to this point, the method is the same as the conventional method.

この種菌を、下記表に示す組成の変法VL寒天培地又は
その表中の寒天を除いた組成の変法VL液体培地により
培養し元菌を作製する。
This inoculum is cultured in a modified VL agar medium having the composition shown in the table below or a modified VL liquid medium having a composition excluding the agar in the table to prepare the original bacterium.

即ち、この種菌を該変法液体培地に接種し、嫌気条件下
で、37℃、1〜2日培養後、無菌的に遠心(3,000〜
8,000rpm、10〜30分間)し、遠心上清を捨て、沈渣
菌体を滅菌リン酸緩衝食塩液(pH7.0〜7.2)(滅菌生理
食塩液、あるいは滅菌精製水でもよい)に懸濁し、元菌
を得る。或は、前記種菌を、さらに半固形培地にした該
変法VL寒天培地に塗布し、嫌気的に37℃で1〜2日
間培養し、その菌苔を滅菌リン酸緩衝食塩液(pH7.0〜
7.2)(滅菌生理食塩液あるいは滅菌精製水でもよい)
に懸濁し、さらにこれを1〜2回繰り返し、菌体を洗浄
(遠心はいずれも3,000〜8,000rpm、10〜30分間で
ある)後、再び滅菌リン酸緩衝食塩液(pH7.0〜7.2)
(滅菌生理食塩液あるいは滅菌精製水でもよい)に懸濁
し、これを元菌とする。
That is, this modified inoculum was inoculated into the modified liquid medium, cultured under anaerobic conditions at 37 ° C for 1 to 2 days, and then aseptically centrifuged (3,000 to
After centrifugation at 8,000 rpm for 10 to 30 minutes, the centrifugation supernatant is discarded, and the precipitated bacterial cells are suspended in sterile phosphate buffered saline (pH 7.0 to 7.2) (sterile physiological saline or sterile purified water may be used). Get the original fungus. Alternatively, the above-mentioned inoculum is further applied to the modified VL agar medium which is further made into a semisolid medium, and anaerobically cultured at 37 ° C. for 1 to 2 days, and the moss is sterilized with phosphate buffered saline (pH 7.0). ~
7.2) (Sterile physiological saline or sterile purified water may be used)
The cells are then suspended again and again 1 to 2 times to wash the cells (centrifugation is 3,000 to 8,000 rpm for 10 to 30 minutes), and then sterile phosphate buffered saline (pH 7.0 to 7.2).
Suspend in sterile physiological saline or sterile purified water, and use this as the original bacterium.

次に、別個に、あらかじめ滅菌した半透膜(分画分子量
8,000〜10,000の透析膜チユーブから作る)を、無菌的
に貼り付けた半固形培地である変法VL寒天培地(前記
と同じ組成培地)の半透膜上に、例えば、液体培養によ
る元菌の懸濁させた培養菌液(湿菌量約10mg/ml)0.1ml
を均一に塗布後、嫌気的に37℃で1〜2日間培養を行
う(本培養)。本培養後、培地面の半透膜を剥ぎ取り、
0.1Mトリス・塩酸緩衝液pH8.0で洗浄し、その洗浄液に
ついて遠心分離(8,000rpm、30分間)を行つて、菌体
とプロテアーゼ抗原を含む上清とに分離する。菌体は遠
心管底に菌体塊として残るので、上清液のみ回収する。
回収された上清中にはプロテアーゼ抗原と低分子量の培
地成分および緩衝液成分等が含まれる。この上清液を半
透膜チユーブ(分画分子量8,000〜20,000)に詰め、冷
暗室(約4℃)で濃縮剤(AGガムあるいはポリエチレ
ングリコール#6,000等)で処理して濃縮し、純度の高
いプロテアーゼ抗原を得る。回収されたプロテアーゼ抗
原液はボツクス・タイトレーシヨンによつて活性単位を
決定した。(その抗原活性(寒天ゲル内沈降試験)は
1:32〜1:62であつた。又その液中には色素が認めら
れなかつた。)一定の単位抗原になるように0.1Mトリ
ス・塩酸緩衝液pH8.0を加え、プロテアーゼ抗原が変性
・失活しない真空凍結乾燥法で凍結乾燥し、診断用プロ
テアーゼ抗原を得た。
Then, separately, pre-sterilized semipermeable membrane (cut off molecular weight
8,000 to 10,000 dialysis membrane tubes) are aseptically attached to the semipermeable membrane of the modified VL agar medium (medium having the same composition as above), which is a semisolid medium. 0.1 ml of suspended culture fluid (wet bacterium amount about 10 mg / ml)
Is evenly applied, and then anaerobically cultured at 37 ° C. for 1 to 2 days (main culture). After the main culture, peel off the semipermeable membrane on the medium surface,
The cells are washed with 0.1 M Tris / HCl buffer (pH 8.0), and the washed solution is centrifuged (8,000 rpm, 30 minutes) to separate the cells and the supernatant containing the protease antigen. Since the cells remain as a cell mass on the bottom of the centrifuge tube, only the supernatant is collected.
The recovered supernatant contains protease antigens, low molecular weight medium components, buffer components, and the like. This supernatant is packed in a semipermeable membrane tube (molecular weight cut-off of 8,000 to 20,000), treated with a condensing agent (AG gum or polyethylene glycol # 6,000, etc.) in a cool dark room (about 4 ° C) and concentrated to obtain a high purity. Obtain the protease antigen. The activity unit of the recovered protease antigen solution was determined by Box Titration. (The antigenic activity (sedimentation test in agar gel) was 1:32 to 1:62. No dye was found in the solution.) 0.1M Tris-hydrochloric acid so as to become a constant unit antigen Buffer solution pH8.0 was added and freeze-dried by a vacuum freeze-drying method in which the protease antigen was not denatured or inactivated to obtain a diagnostic protease antigen.

比較例1 精製水3に溶解する各培地成分の量を2.7の精製水
に溶解した変法VL液体培地中に半透膜袋を懸垂し、そ
の半透膜袋中に前記実施例1で得た同じ元菌であるアク
チノマイセス・ピオゲネス(Actinomyces pyogenes)菌
の懸濁液300mlを入れ、炭酸ガス培養後、半透膜袋を取
り出し、遠心分離によつて菌体とアクチノマイセス・ピ
オゲネス菌が産生したプロテアーゼ(蛋白分解酵素)抗
原が含まれる上清とに分離し、その上清を回収し、濃縮
したところ1:32以上の抗原活性(寒天ゲル内沈降試
験)を示すプロテアーゼ抗原液が約5〜15mlと少量し
か得られなかつた。しかも培地中に含まれる低分子量の
色素等が混入していた。これら物質の除去のため精製
水、および生理食塩液、緩衝液等で透析してもそれ等が
除去されなかつた。
Comparative Example 1 A semipermeable membrane bag was suspended in a modified VL liquid medium in which the amount of each medium component dissolved in purified water 3 was dissolved in 2.7 purified water, and the semipermeable membrane bag was obtained in Example 1 above. Put 300 ml of suspension of Actinomyces pyogenes, which is the same original bacteria, and after culture with carbon dioxide, take out the semipermeable membrane bag and centrifuge to separate the cells and Actinomyces pyogenes. Was separated into a supernatant containing a protease (proteolytic enzyme) antigen produced by, and the supernatant was collected and concentrated to obtain a protease antigen solution showing an antigen activity (precipitation test in agar gel) of 1:32 or more. Only a small amount of about 5 to 15 ml was obtained. Moreover, low-molecular weight pigments contained in the medium were mixed. Even if they were dialyzed against purified water, physiological saline solution, buffer solution or the like to remove these substances, they were not removed.

比較例2 実施例1によつて得たアクチノマイセス・ピオゲネスの
変法VL液体培養菌液の元菌を約17倍量の変法VL液体
培地に接種し、炭酸ガス培養し、遠心分離によつて菌体
と培地中に産生されたプロテアーゼ(蛋白分解酵素)抗
原を含む上清とに分離し、その上清を半透膜チユーブに
詰め、濃縮剤で約1/10に濃縮し、さらに緩衝液で塩析し
た後、その上清を分画分子量の異なる2種の限外過膜
(分画分子量:30万および1万)を用いた限外過法
で、プロテアーゼ抗原を一定濃度に濃縮・精製した。そ
の製造日数が11〜15日間要した。
Comparative Example 2 The original strain of the modified VL liquid culture of the Actinomyces pyogenes obtained according to Example 1 was inoculated in about 17 times the amount of the modified VL liquid medium, carbon dioxide-cultured, and centrifuged. Therefore, the cells and the supernatant containing the protease (proteolytic enzyme) antigen produced in the medium are separated, and the supernatant is packed in a semipermeable membrane tube and concentrated to about 1/10 with a concentrating agent. After salting out with a buffer solution, the supernatant was subjected to an ultrafiltration method using two ultrafiltration membranes with different molecular weight cutoffs (molecular weight cutoffs: 300,000 and 10,000) to bring the protease antigen to a constant concentration. Concentrated and purified. The number of manufacturing days required 11 to 15 days.

実施例1の本発明の製法で要する6〜7日と比較して2
倍以上の日数を要した。
2 as compared with 6 to 7 days required in the production method of the present invention in Example 1
It took more than double the number of days.

比較試験例1 実施例1によつて得られた本発明品と比較例2によつて
得られた従来品との蛋白質抗原標品(診断用プロテアー
ゼ抗原)について、その1バイアルを32倍量の蒸溜水
で希釈し、その吸収波長を比較検討した。その結果を添
付図面に示す。この図はアクチノマイセス・ピオゲネス
感染症診断用プロテアーゼ抗原の紫外・可視吸収図を示
したもので、この図から、本発明品(破線)について
は、可視波長領域で全く吸収を示さず、無色透明の溶液
となるが、一方従来品(実線)ではかなりの吸収を示
し、着色された溶液であることがわかる。
Comparative Test Example 1 For a protein antigen preparation (diagnostic protease antigen) of the product of the present invention obtained in Example 1 and the conventional product obtained in Comparative Example 2, one vial of 32 times amount was prepared. It was diluted with distilled water and the absorption wavelengths were compared and examined. The results are shown in the attached drawings. This figure shows an ultraviolet-visible absorption diagram of a protease antigen for diagnosing Actinomyces pyogenes infectious disease. From this figure, the product of the present invention (dashed line) shows no absorption in the visible wavelength region and is colorless. Although it is a transparent solution, the conventional product (solid line) shows a considerable absorption, indicating that it is a colored solution.

比較試験例2 実施例1に示す本発明の製法と比較例2に示す従来の製
法とによるプロテアーゼ抗原液の収量を比較した。
Comparative Test Example 2 The yield of the protease antigen solution was compared between the production method of the present invention shown in Example 1 and the conventional production method shown in Comparative Example 2.

その結果を下記第2表に示す。The results are shown in Table 2 below.

上記表から明らかなように、6回の試作で培地1当り
の最終的回収抗原溶液について、本発明法は約18〜2
0mlであつたのに対して、従来法は約9〜11mlで、本
発明法が約1.9倍も多い収量が得られた。また、蛋白質
の比較で、本発明法は16.668mg〜18.68mg、従来法は7.1
82mg〜8.745mgで、平均約2.2倍も本発明法が多かつた。
As is clear from the above table, the method of the present invention was applied to about 18 to 2 of the final recovered antigen solution per medium in 6 trials.
The amount of the conventional method was about 9 to 11 ml, while the yield of the method of the present invention was about 1.9 times higher than that of 0 ml. Further, in comparison of proteins, the method of the present invention is 16.668 mg to 18.68 mg, and the conventional method is 7.1.
It was 82 mg to 8.745 mg, and the number of the method of the present invention was about 2.2 times as large as the average.

(発明の効果) このように本発明によるときは、半固形培地上に該培地
中の栄養成分は通過させるが、蛋白質抗原を通過させな
い半透膜を付着し、その半透膜上に、家畜、(禽)の病
原性細菌の培養菌液を塗布し、本培養を行うようにした
ので、半透膜上に、産生された蛋白質抗原は、培地中の
高分子物質、色素などの不純物との混合なしに得ること
ができると共に、その生産性が向上し得られる等の効果
を有する。また、本培養後は、該半透膜を半固形培地か
ら剥離し、その半透膜を洗浄し、得られた洗浄液から蛋
白質抗原を回収するので、従来法に比し産生蛋白質抗原
液の濃縮、精製が容易になし得られ、分離、回収、精製
作業が容易となり、また短時間に且つ高収率に而も高品
質の蛋白質抗原を製造することができる等の効果を有す
る。
(Effects of the Invention) As described above, according to the present invention, a semipermeable membrane that allows nutrient components in the medium to pass therethrough but does not allow protein antigens to pass through is attached to the semisolid medium, and the livestock is attached to the semipermeable membrane. , (Poultry) pathogenic bacterium culture liquid was applied and main culture was performed, so that the protein antigen produced on the semipermeable membrane was mixed with impurities such as polymer substances and pigments in the medium. Can be obtained without mixing, and the productivity can be improved. Further, after the main culture, the semipermeable membrane is peeled from the semisolid medium, the semipermeable membrane is washed, and the protein antigen is recovered from the obtained washing solution, so that the concentration of the produced protein antigen solution is higher than that in the conventional method. Further, there are effects such that purification can be easily carried out, separation, recovery and purification operations are facilitated, and a protein antigen of high quality can be produced in a short time and in a high yield.

【図面の簡単な説明】[Brief description of drawings]

図面は、本法並に従来法により得られた蛋白質抗原製品
の紫外可視吸収特性曲線を示すグラフである。
The drawing is a graph showing the UV-visible absorption characteristic curves of protein antigen products obtained by this method as well as the conventional method.

───────────────────────────────────────────────────── フロントページの続き (51)Int.Cl.5 識別記号 庁内整理番号 FI 技術表示箇所 (C12P 21/00 C12R 1:44) (C12P 21/00 C12R 1:46) (C12P 21/00 C12R 1:01) ─────────────────────────────────────────────────── ─── Continuation of the front page (51) Int.Cl. 5 Identification code Internal reference number FI Technical indication (C12P 21/00 C12R 1:44) (C12P 21/00 C12R 1:46) (C12P 21/00 C12R 1:01)

Claims (3)

【特許請求の範囲】[Claims] 【請求項1】半固形培地上に該培地中の栄養成分は通過
させるが、蛋白質抗原を通過させない半透膜を付着し、
その半透膜上に家畜(禽)の病原性細菌の培養菌液を塗
布し、本培養を行い、蛋白質抗原を該半透膜上に産生さ
せた後、その半透膜をその産生した蛋白質抗原と共に半
固形培地から剥離し、次で該半透膜を洗浄し、得られた
洗浄液から該抗原を菌体と分離して回収することを特徴
とする蛋白質抗原の製法。
1. A semi-permeable medium is attached with a semi-permeable membrane that allows nutrient components in the medium to pass through but does not pass protein antigens.
A culture solution of a pathogenic bacterium of domestic animals (poultry) is applied onto the semipermeable membrane, main culture is performed, and a protein antigen is produced on the semipermeable membrane, and then the semipermeable membrane is produced by the produced protein. A method for producing a protein antigen, which comprises peeling from an semi-solid medium together with an antigen, then washing the semi-permeable membrane, and separating and recovering the antigen from bacterial cells from the resulting washing solution.
【請求項2】半透膜の文画分子量は、3,500〜50,000で
ある特許請求の範囲1に記載の製法。
2. The method according to claim 1, wherein the semipermeable membrane has a drawing molecular weight of 3,500 to 50,000.
【請求項3】病原性細菌は、アクチノマイセス属、ボル
デテラ属、パスツレラ属、スタフイロコツカス属、スト
レプトコツカス属、フソバクテリウム属、アクチノバチ
ラス属およびヘモフイルス属に属するものである特許請
求の範囲1に記載の製法。
3. The pathogenic bacterium belongs to the genus Actinomyces, the genus Bordetella, the genus Pasteurella, the genus Staphylococcus, the genus Streptococcus, the genus Fusobacterium, the genus Actinobacillus and the genus Haemophilus. The manufacturing method according to 1.
JP61021245A 1986-02-04 1986-02-04 Method for producing protein antigen produced by pathogenic bacteria in livestock and poultry Expired - Lifetime JPH0632630B2 (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
JP61021245A JPH0632630B2 (en) 1986-02-04 1986-02-04 Method for producing protein antigen produced by pathogenic bacteria in livestock and poultry

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
JP61021245A JPH0632630B2 (en) 1986-02-04 1986-02-04 Method for producing protein antigen produced by pathogenic bacteria in livestock and poultry

Publications (2)

Publication Number Publication Date
JPS62181797A JPS62181797A (en) 1987-08-10
JPH0632630B2 true JPH0632630B2 (en) 1994-05-02

Family

ID=12049672

Family Applications (1)

Application Number Title Priority Date Filing Date
JP61021245A Expired - Lifetime JPH0632630B2 (en) 1986-02-04 1986-02-04 Method for producing protein antigen produced by pathogenic bacteria in livestock and poultry

Country Status (1)

Country Link
JP (1) JPH0632630B2 (en)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2694196B1 (en) 2011-04-01 2021-07-21 EMD Millipore Corporation Nanofiber containing composite structures
SG10201911354UA (en) * 2014-06-26 2020-02-27 Emd Millipore Corp Filter structure with enhanced dirt holding capacity
CN109010823B (en) * 2018-08-27 2022-03-18 广州汇高生物科技有限公司 Composition for resisting various pathogenic bacteria, preparation process and application thereof, spray and preparation process thereof

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS59113897A (en) * 1982-11-01 1984-06-30 マイルス・ラボラトリ−ス・インコ−ポレ−テツド Detection and separation of microorganism

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS59113897A (en) * 1982-11-01 1984-06-30 マイルス・ラボラトリ−ス・インコ−ポレ−テツド Detection and separation of microorganism

Also Published As

Publication number Publication date
JPS62181797A (en) 1987-08-10

Similar Documents

Publication Publication Date Title
Avery et al. Studies on the chemical nature of the substance inducing transformation of pneumococcal types: induction of transformation by a desoxyribonucleic acid fraction isolated from pneumococcus type III
Tillett et al. The fibrinolytic activity of hemolytic streptococci
Shattock The Streptococci of Group D; the Seroloǵical Groupinǵ of Streptococcus bovis and Observations on Seroloǵically Refractory Group D Strains
Malmquist et al. Isolation, immunodiffusion, immunofluorescence, and electron microscopy of a syncytial virus of lymphosarcomatous and apparently normal cattle
Avery et al. Studies on the chemical nature of the substance inducing transformation of pneumococcal types. Inductions of transformation by a desoxyribonucleic acid fraction isolated from pneumococcus type III.
Sternberg A manual of bacteriology
Skerman et al. Differentiation of Bacteroides nodosus biotypes and colony variants in relation to their virulence and immunoprotective properties in sheep
JPH0779684B2 (en) Bifidobacteria growth promoting composition
Valle et al. Staphylococci isolated from healthy goats
CN109954135B (en) Inactivated toxoid vaccine of clostridium perfringens type A cattle and preparation method thereof
Sternberg A text-book of bacteriology
JPH0632630B2 (en) Method for producing protein antigen produced by pathogenic bacteria in livestock and poultry
Smith et al. A Method for Collecting Bacteria and their Products from Infections in Experimental Animals with Special Reference to Bacillus anthracis
CN115216424A (en) Culture passage and preservation method of mycoplasma synoviae
Brent Nutritional studies on the amoebo-flagellate, Tetramitus rostratus
JP2660908B2 (en) Yogurt with good bifidobacterial growth promotion and survival
Domermuth et al. A medium for isolation and tentative identification of fecal streptococci, and their role as avian pathogens
Pollock et al. Comparison of undefined medium and its dialyzable fraction for growth of Mycoplasma
JPS5852227A (en) Immunogenic composite body from gonococcus
JPH04300898A (en) New glycoprotein conjugate and production thereof
JP4363603B2 (en) Pure separation method of derobibrio and mass pure culture method of derobibrio
RU2158302C2 (en) Nutrient medium for bifidobacterium and lactobacterium culturing
RU2131263C1 (en) Method of tuberculin preparing
JPS5978122A (en) Preparation of colony stimulating factor
US2268955A (en) Bacterial product and bacteria strain and process of producing the same